menu search

PRLD / Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Read More
Posted: Apr 11 2023, 08:30
Author Name: GlobeNewsWire
Views: 103074

PRLD News  

All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy

By Zacks Investment Research
October 4, 2023

All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy

Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Za more_horizontal

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

By GlobeNewsWire
April 11, 2023

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline more_horizontal

Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate

By Zacks Investment Research
March 16, 2023

Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate

Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients. more_horizontal

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

By GlobeNewsWire
February 9, 2023

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology co more_horizontal


Search within

Pages Search Results: